Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study - PDF (俄文)
版权所有 © Consilium Medicum, 2023
![Creative Commons License](http://licensebuttons.net/l/by-nc-sa/4.0/88x31.png)
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。